BioNeutral Group, Inc. Announces Company Shareholder Update
June 05 2014 - 8:00AM
Marketwired
BioNeutral Group, Inc. Announces Company Shareholder Update
NEWARK, NJ--(Marketwired - Jun 5, 2014) - BioNeutral Group, Inc.
(OTC Pink: BONU) (PINKSHEETS: BONU),
I would like to take a moment to thank you for your continued
support in the past and brief you on some of the new important
developments with the company. In the past as you know we've
communicated with stockholders primarily through our filings and
periodic press releases. Now that the commercialization stage of
the company's development has begun to unfold we will endeavor to
do it not only more frequently but directly.
Over the last year, the company has developed and continually
modified a comprehensive business plan to include all aspects of
the business, finance, operations, sales, marketing and R&D,
the focus of which is to commercially leverage our technology.
During that time, we completed our independent testing of our
YGIENE™ sterilant, recruited key sales executives, important
consultants and independent members of our board of directors. We
also brought two law suits one seeking to regain the lost
distribution rights in Asia and Europe and the other to recover
damages from what proved to be fraudulently granted contracts. Both
these suits proved to be successful.
Beginning in 2013, we began to commercialize our YGIENE™
technology. Most importantly, we learned that there was a
significant need for YGIENE™ and that the product performed as
promised under actual marketplace conditions. Building on this
strength over the last five months we've established relationships
with three key distributors. Each one specializes in at least one
of three key markets of interest, lab research, Long Term Care and
mold remediation among others. As a result, we now as of this month
are represented by approximately 115 sales representatives in
various parts of the country who will not only be presenting our
products to their customers but exhibiting them at key industry
trade events. In addition, we have several Private Label
discussions under way with various manufacturers both in the U.S.
and overseas as well as continuing conversations with additional
U.S. distributors. These discussions, if proven fruitful would
position the company in important additional market segments as
well.
Based on the initial highly favorable impression YGIENE™ has
made on the trade we introduced in 2014 a line extension program
aimed at broadening our product line to include a YGIENE™ Cleaner
and an OGIENE™ Air freshener both to be available in several
versions. These new products offer unsurpassed end benefits
commiserate with the basic YGIENE™ selling proposition and as such
each complements the other. We have also in the first half of
this year begun initial development of new exciting applications of
our basic technology, which while somewhat longer term in nature,
will broaden the current product line even further.
In addition, we have entered into a distribution agreement to
market a consumer version of our OGIENE™ air freshener in the U.K
with eventual expansion to the balance of Europe. As a result of
this activity, we believe that the business will soon begin to have
"traction" (certainly the enthusiasm of our Distributors, each of
whom are, and for a long time have been, market participants, seem
to think so) and we anticipate that we will soon be operating at a
meaningful level of sales.
As you are undoubtedly aware during this time our stock price
has declined significantly. This is due, we believe, to the fact
that we've been forced to significantly increase our share base in
order to fund our working capital needs. As we continue to expand
our commercialization process, bringing news to the marketplace in
the process hopefully our share price will increase.
Lastly, we are pleased to have recently engaged the STAT Group
to assist us in communicating our current developments and
answering investor and media inquiries. S.T.A.T. representatives
have been helping small capitalized companies for over a decade
communicate with the investing community.
Sincerely, /s/Mark Lowenthal, President & CEO
About BioNeutral Group, Inc. Headquartered in Newark, New
Jersey, BioNeutral Group, Inc., is a specialty technology-based
life-science company that has developed a technology platform that
neutralizes harmful environmental contaminants, toxins and
dangerous micro-organisms including bacteria, viruses, mold, fungi
and spores. BioNeutral's products, YGIENE™ and OGIENE™ kill germs
and clean surfaces with a dramatic increase in speed and power over
their rivals in the marketplace. BioNeutral's proprietary platform
technology has been proven effective in surface, water and airborne
applications. Auto Neutral is a registered trademark of BioNeutral
Group, Inc. For more information on BioNeutral, including a listing
of company products, leadership and background please visit
www.bioneutral.com.
Find us on Facebook:
http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
Forward-Looking Statements: This release contains
certain "forward-looking statements" relating to the business of
the Company and its subsidiary companies. These forward-looking
statements are often identified by the use of forward-looking
terminology such as "believes," "expects" or similar expressions.
Such forward-looking statements involve known and unknown risks and
uncertainties that may cause actual results to be materially
different from those described herein as anticipated, believed,
estimated or expected. Investors should not place undue reliance on
these forward-looking statements, which speak only as of the date
of this press release. The Company's actual results could differ
materially from those anticipated in these forward-looking
statements as a result of a variety of factors, including those
described in the Company's filings with the Securities and Exchange
Commission. BioNeutral routinely tests its formulations against
those of its competitors. The results are published to let
shareholders know how the Company's technology compares with known
formulations in the market place. Any product claim for
antimicrobial activity requires approval from the EPA or FDA,
depending upon where and how the formulations are used. The EPA has
approved and registered the Company's data and findings specific to
YGIENE-206. BioNeutral's antimicrobial formulations will be
marketed under the brand name YGIENE™ and are available for sale in
the United States.
CONTACTS: FOR THE COMPANY: Mark Lowenthal CEO BioNeutral Group,
Inc. +1-973-577-8003 Craig Fisher S.T.A.T Group LLC
+1-786-375-0556